Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Non-invasive scan could replace risky procedure for adrenal tumor diagnosis

NCT ID NCT06100367

Diagnosis Sponsor: Changi General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special PET scan (11C-Metomidate) to better identify adrenal tumors that cause high blood pressure and can be cured with surgery. About 100 adults with suspected adrenal-related hypertension will receive the scan, which is non-invasive and may replace the current difficult vein-sampling procedure. The goal is to accurately find patients who can be cured by removing the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For patients with primary aldosteronism (PA\_CURE 2 / PA\_MTO EH): 1. Confirmed diagnosis of primary aldosteronism, as defined in Endocrine Society Guidelines 2016, with positive confirmatory test (post-salt loading aldosterone \>140pmol/L); or hypokalemia with undetectable renin levels and aldosterone \>550pmol/L; or likely primary aldosteronism / low-renin hypertension (inappropriate aldosterone levels and suppressed renin levels) 2. Keen for surgical treatment if shown to have unilateral adrenal disease. * For patients with suspected adrenal tumors (PA\_MTO AT) 1. All patients with suspected adrenal tumors based on imaging and clinical suspicion. Exclusion Criteria: * Inability to provide written informed consent. * Chronic renal failure of Stage 3b or greater severity, estimated glomerular filtration rate (eGFR) \< 45ml/min/1.73m2 using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. (only applicable for PA\_CURE 2 / PA\_MTO EH) * Severe or terminal medical condition(s) that in the view of the investigator prohibits participation in the study or interferes with possible treatment or health-related quality of life, e.g. cancer, end-stage liver disease, end stage renal failure (only applicable for PA\_CURE 2 / PA\_MTO EH) * Contraindications to isotope scanning (e.g. Female patients who are pregnant (self-declared or via positive pregnancy test), intending to become pregnant (within 3 months of scan) or breastfeeding) or CT Scan, which includes but not limited to waist circumference \>140cm, morbid obesity or claustrophobia (limiting entry in CT scanner) * Contraindication to ingestion of corticosteroids (e.g. poorly controlled diabetes, HbA1C \>13%)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal gland cancer adrenal gland neoplasm aldosterone-producing adrenal cortex adenoma hyperaldosteronism Neoplasm Metastasis primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal tumors Primary aldosteronism Primary aldosteronism due to aldosterone producing adenoma

Contacts and locations

Locations

  • Changi General Hospital

    Singapore, Singapore

  • Khoo Teck Puat Hospital

    Singapore, Singapore

  • National University Hospital

    Singapore, Singapore

  • Ng Teng Fong General Hospital

    Singapore, Singapore

  • Sengkang General Hospital

    Singapore, Singapore

  • Singapore General Hospital

    Singapore, Singapore

  • Tan Tock Seng Hospital

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.